Loading institutional data...
Loading institutional data...
Held by 3,895 of 5,944 reporting institutions (100th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
Peers = companies sharing ABBV's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $264.02 today, the market must believe free cash flow compounds 12.0%/yr for a decade (off $19.2B normalized FCF).
The market's 12.0% is more optimistic than its 8-yr track record.
2-stage DCF · 1.77B shares · net debt $61.8B
mean 10.0% · volatility σ 21% · implied rate exceeded in 3/8 yrs
Central path = implied 12.0%/yr growth; shaded band = ±1σ (21%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 65% of free cash flow, leaving room to grow it and fund buybacks. Last year: $11.7B dividends + $980M buybacks = $12.6B returned on $17.8B FCF.
9 consecutive years of dividend increases · 12%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Modest payoff on reinvested capital. Current ROIC on all capital: 7%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $5.2B is below the $6.0B due within a year — relies on refinancing or operating cash flow. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Coverage is adequate but not comfortable. Effective rate ~4.3% on $67.0B of debt.
Cash of $5.2B fully covers short-term debt of $2.5B.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61.16B 100.0% | $56.33B 100.0% | $54.32B 100.0% | $58.05B 100.0% | $56.20B 100.0% | $45.80B 100.0% | $33.27B 100.0% | $32.75B 100.0% | $28.22B 100.0% | $25.64B 100.0% |
| Cost of Revenue | $18.20B 29.8% | $16.90B 30.0% | $20.41B 37.6% | $17.41B 30.0% | $17.45B 31.0% | $15.39B 33.6% | $7.44B 22.4% | $7.72B 23.6% | $7.04B 25.0% | $5.83B 22.7% |
| Cost of Products | — | — | — | — | — | — | — | — | $7.04B 25.0% | $5.83B 22.8% |
| Selling, General & Admin | $14.01B 22.9% | $14.75B 26.2% | $12.87B 23.7% | $15.26B 26.3% | $12.35B 22.0% | $11.30B 24.7% | $6.94B 20.9% | $7.40B 22.6% | $6.29B 22.3% | $5.88B 22.9% |
| Total Operating Expenses | $46.09B 75.4% | $47.20B 83.8% | $41.56B 76.5% | $39.94B 68.8% | $38.27B 68.1% | $34.44B 75.2% | $20.28B 61.0% | $26.37B 80.5% | $18.67B 66.2% | $16.30B 63.6% |
| Operating Income | $15.07B 24.6% | $9.14B 16.2% | $12.76B 23.5% | $18.12B 31.2% | $17.92B 31.9% | $11.36B 24.8% | $12.98B 39.0% | $6.38B 19.5% | $9.54B 33.8% | $9.34B 36.4% |
| Interest Expense | $2.89B 4.7% | $2.81B 5.0% | $2.22B 4.1% | $2.23B 3.8% | $2.42B 4.3% | $2.45B 5.4% | $1.78B 5.4% | $1.35B 4.1% | $1.15B 4.1% | $1.05B 4.1% |
| Other Income (Expense), net | -$5.79B -9.5% | -$3.24B -5.8% | -$4.68B -8.6% | -$2.45B -4.2% | -$2.50B -4.4% | -$5.61B -12.3% | -$3.01B -9.0% | -$18.0M -0.1% | -$466.0M -1.7% | -$188.0M -0.7% |
| Pretax Income | $6.60B 10.8% | $3.72B 6.6% | $6.25B 11.5% | $13.48B 23.2% | $12.99B 23.1% | $3.40B 7.4% | $8.43B 25.3% | $5.20B 15.9% | $7.73B 27.4% | $7.88B 30.8% |
| Income Tax Expense | $2.36B 3.9% | -$570.0M -1.0% | $1.38B 2.5% | $1.63B 2.8% | $1.44B 2.6% | -$1.22B -2.7% | $544.0M 1.6% | -$490.0M -1.5% | $2.42B 8.6% | $1.93B 7.5% |
| Net Income | $4.23B 6.9% | $4.28B 7.6% | $4.86B 9.0% | $11.84B 20.4% | $11.54B 20.5% | $4.62B 10.1% | $7.88B 23.7% | $5.69B 17.4% | $5.31B 18.8% | $5.95B 23.2% |
| Per Share | ||||||||||
| EPS (Basic) | $2.37 | $2.40 | $2.73 | $6.65 | $6.48 | $2.73 | $5.30 | $3.67 | $3.31 | $3.65 |
| EPS (Diluted) | $2.36 | $2.39 | $2.72 | $6.63 | $6.45 | $2.72 | $5.28 | $3.66 | $3.30 | $3.63 |
| Weighted Avg Shares (Basic) | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | 1.67B | 1.48B | 1.54B | 1.60B | 1.62B |
| Weighted Avg Shares (Diluted) | 1.77B | 1.77B | 1.77B | 1.78B | 1.78B | 1.67B | 1.48B | 1.55B | 1.60B | 1.63B |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 98th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 7.6× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 23.6 | 22.4 | 33.6 | 31.0 | 30.0 | 37.6 | 30.0 | 29.8 |
| SG&A | 22.6 | 20.9 | 24.7 | 22.0 | 26.3 | 23.7 | 26.2 | 22.9 |
| Operating Income | 19.5 | 39.0 | 24.8 | 31.9 | 31.2 | 23.5 | 16.2 | 24.6 |
| Income Tax | -1.5 | 1.6 | -2.7 | 2.6 | 2.8 | 2.5 | -1.0 | 3.9 |
| Net Income | 17.4 | 23.7 | 10.1 | 20.5 | 20.4 | 9.0 | 7.6 | 6.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ABBV: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.